Madhur Nayan1, Michael A S Jewett1, Lynn Anson-Cartwright1, Philippe L Bedard2, Malcolm Moore2, Peter Chung3, Padraig Warde3, Joan Sweet4, Martin O'Malley5, Robert J Hamilton1. 1. Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada. 2. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Toronto, ON, Canada. 3. Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada. 4. Department of Pathology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada. 5. Department of Medical Imaging, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada.
Abstract
INTRODUCTION: Institutional experience has been associated with improved outcomes for various malignancies, including testicular cancer. The present study evaluated whether institution at orchiectomy was associated with outcomes on active surveillance (AS) for clinical stage (CS) I germ cell tumours (GCT). METHODS: 815 patients with CSI GCT managed with AS at the Princess Margaret Cancer Centre were identified. Princess Margaret is a tertiary academic institution with a multidisciplinary testicular cancer clinic involving radiation oncologists, medical oncologists, and urologists, and has research experience in testicular cancer care. The association between institution of orchiectomy (Princess Margaret vs. Other) and time to progression on AS was analyzed using multivariable Cox proportional hazards models. Academic vs. non-academic institutions were compared in a sensitivity analysis. RESULTS: Patients undergoing orchiectomy at Princess Margaret for non-seminoma GCT were significantly less likely to have pure embryonal carcinoma (EC) in orchiectomy pathology (odds ratio [OR] 0.33; p=0.008) and CSIB disease (OR 0.47; p=0.014). Seminoma characteristics did not differ significantly between institution groups. In non-seminoma GCT, median followup was 5.4 years, 27% progressed on AS, and institution of orchiectomy was not associated with time to progression in either univariate (hazard ratio [HR] 0.79; p=0.33) or multivariable analyses (HR 1.01; p=0.97). In seminoma, median followup was 4.7 years, 12% progressed on AS, and institution of orchiectomy was not associated with progression (univariate: HR 0.87; p=0.73; multivariable: HR 0.98; p=0.96). Sensitivity analyses demonstrated similar results. CONCLUSIONS: Among CSI GCT patients managed on AS at a specialized cancer centre, there appears to be no difference in oncologic outcomes based upon the institution where orchiectomy was performed.
INTRODUCTION: Institutional experience has been associated with improved outcomes for various malignancies, including testicular cancer. The present study evaluated whether institution at orchiectomy was associated with outcomes on active surveillance (AS) for clinical stage (CS) I germ cell tumours (GCT). METHODS: 815 patients with CSI GCT managed with AS at the Princess Margaret Cancer Centre were identified. Princess Margaret is a tertiary academic institution with a multidisciplinary testicular cancer clinic involving radiation oncologists, medical oncologists, and urologists, and has research experience in testicular cancer care. The association between institution of orchiectomy (Princess Margaret vs. Other) and time to progression on AS was analyzed using multivariable Cox proportional hazards models. Academic vs. non-academic institutions were compared in a sensitivity analysis. RESULTS:Patients undergoing orchiectomy at Princess Margaret for non-seminoma GCT were significantly less likely to have pure embryonal carcinoma (EC) in orchiectomy pathology (odds ratio [OR] 0.33; p=0.008) and CSIB disease (OR 0.47; p=0.014). Seminoma characteristics did not differ significantly between institution groups. In non-seminoma GCT, median followup was 5.4 years, 27% progressed on AS, and institution of orchiectomy was not associated with time to progression in either univariate (hazard ratio [HR] 0.79; p=0.33) or multivariable analyses (HR 1.01; p=0.97). In seminoma, median followup was 4.7 years, 12% progressed on AS, and institution of orchiectomy was not associated with progression (univariate: HR 0.87; p=0.73; multivariable: HR 0.98; p=0.96). Sensitivity analyses demonstrated similar results. CONCLUSIONS: Among CSI GCT patients managed on AS at a specialized cancer centre, there appears to be no difference in oncologic outcomes based upon the institution where orchiectomy was performed.
Authors: Peter Swindle; James A Eastham; Makoto Ohori; Michael W Kattan; Thomas Wheeler; Norio Maru; Kevin Slawin; Peter T Scardino Journal: J Urol Date: 2005-09 Impact factor: 7.450
Authors: Christian Kollmannsberger; Torgrim Tandstad; Philippe L Bedard; Gabriella Cohn-Cedermark; Peter W Chung; Michael A Jewett; Tom Powles; Padraig R Warde; Siamak Daneshmand; Andrew Protheroe; Scott Tyldesley; Peter C Black; Kim Chi; Alan I So; Malcom J Moore; Craig R Nichols Journal: J Clin Oncol Date: 2014-08-18 Impact factor: 44.544
Authors: Danny Vesprini; Peter Chung; Shaun Tolan; Mary Gospodarowicz; Michael Jewett; Martin O'Malley; Joan Sweet; Malcolm Moore; Tony Panzarella; Jeremy Sturgeon; Linda Sugar; Lynn Anson-Cartwright; Padraig Warde Journal: Cancer Date: 2012-04-19 Impact factor: 6.860
Authors: N Aass; O Klepp; E Cavallin-Stahl; O Dahl; H Wicklund; B Unsgaard; L Baldetorp; S Ahlström; S D Fosså Journal: J Clin Oncol Date: 1991-05 Impact factor: 44.544
Authors: C Albany; N Adra; A C Snavely; C Cary; T A Masterson; R S Foster; K Kesler; T M Ulbright; L Cheng; M Chovanec; F Taza; K Ku; M J Brames; N H Hanna; L H Einhorn Journal: Ann Oncol Date: 2018-02-01 Impact factor: 32.976
Authors: Peter J Gariscsak; Lynn Anson-Cartwright; Eshetu G Atenafu; Di Maria Jiang; Peter Chung; Philippe Bedard; Padraig Warde; Martin O'Malley; Joan Sweet; Rachel M Glicksman; Robert J Hamilton Journal: Eur Urol Open Sci Date: 2022-04-27